Vedolizumab ELISA (mAb-based)
Enzyme immunoassay for the specific and quantitative determination of free Vedolizumab (Entyvio®) in serum and plasma.
The solid phase (MTP) is coated by a highly specific monoclonal antibody directed against Vedolizumab. Therefore any cross reactivity to the other therapeutical monoclonal antibodies is excluded.
Reference: IG-AB116
Barcode: 8682754930349
Legal Status: CE-Mark
Intended Use: This kit has been developed for the measurement of drug levels in research and diagnostic uses. It is suitable for Therapeutical Drug Monitoring (TDM) purposes.
Assay Design:
Related Documents
Instructions for Use IG-AB116 763.39 KB
Material Safety Data Sheet (MSDS) IG-AB116 268.22 KB
Quality Control Certificates
Quality Control Certificate Lot: AB116-206 296.12 KB
Quality Control Certificate Lot: AB116-205 300.07 KB
Quality Control Certificate Lot: AB116-204 291.20 KB
Quality Control Certificate Lot: AB116-203 160.43 KB
Quality Control Certificate Lot: AB116-202 160.28 KB
Quality Control Certificate Lot: AB116-104 160.78 KB
Quality Control Certificate Lot: AB116-103 160.23 KB
Quality Control Certificate Lot: AB116-102 160.64 KB
Entyvio® is a trademark of Takeda Pharmaceuticals Inc.
The Kit at a glance:
| Required Volume (µL) | 10 |
| Incubation Time (min) | 105 |
| Sample | Serum or Plasma |
| Package Size | 96 Tests |
| Sensitivity (ng/mL, 10x) | 0-1000 |
| Detection Limit (ng/mL) | 2 |
| Spike Recovery (%) | >95 |
| Shelf Life (years) | 2 |
Standard Curve:
